Besivance

Bausch & Lomb Incorporated🇺🇸 United States

FDA Page

Effective Date: Feb 2, 2022
Approval ID: a3e6d688-7e5e-4ca3-b27e-79756c322a32
Products: 1 registered
Version: 19

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use BESIVANCE safely and effectively. See full prescribing information for BESIVANCE. BESIVANCE (besifloxacin ophthalmic suspension), for topical ophthalmic useInitial U.S. Approval: 2009

Quick Stats

Total Products1

Labelers2

Label Sections14

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.